Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)(Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute)) - 药物靶点：CD40L_在研适应症：转移性非小细胞肺癌，复发性非小细胞肺癌_专利_临床

概要

基本信息

药物类型

肿瘤浸润淋巴细胞

别名

CD40L TIL(H. Lee Moffitt Cancer Center and Research Institute)

靶点

CD40L

作用机制

CD40L刺激剂(CD40配体刺激剂)、免疫细胞毒性、T淋巴细胞替代物

治疗领域

肿瘤呼吸系统疾病

在研适应症

转移性非小细胞肺癌复发性非小细胞肺癌

非在研适应症-

原研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

在研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床试验

NCT05768347 / Recruiting临床1期IIT

Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)

The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC).

开始日期2023-08-10

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT05681780 / Recruiting临床1/2期IIT

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

To determine the effect of a special preparation of cells, called tumor-infiltrating lymphocytes (TIL) stimulated with CD40L, when given with the drug nivolumab, for patients with EGFR, ALK, ROS1, or HER2-genomically altered lung cancer.

开始日期2023-01-23

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT03215810 / Completed临床1期IIT

A Phase I Clinical Trial Combining Nivolumab and Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Non-Small Cell Lung Cancer

Investigators plan to study the safety, side effects, and benefits of tumor-infiltrating lymphocytes (TILs) when they are given with the drug nivolumab. Nivolumab is a type of immunotherapy - a drug that is used to boost the ability of the immune system to fight cancer, infection, and other diseases.

开始日期2017-10-11

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+4]

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Tumor-infiltrating Lymphocytes(H. Lee Moffitt Cancer Center and Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
转移性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10
复发性非小细胞肺癌	临床2期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-03-10

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESMO2024	N/A	不可切除的黑色素瘤	102	Tumor Infiltrating Lymphocytes (TIL)	齋選遞觸築選壓蓋簾衊(糧鬱淵窪窪獵獵鏇餘鏇) = ICI-related toxicity was identified in 22 patients (24%), and among those 6 patients (27%) had a recurrence of a toxicity seen with pre-TIL ICI 顧繭鬱製積醖簾糧鹹獵 (襯鏇艱鹹選醖築壓鏇壓 ) 更多	不佳	2024-09-14
ESMO2024	N/A	不可切除的黑色素瘤	102	Immune Checkpoint Inhibitor (ICI) Rechallenge		不佳	2024-09-14
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Initial Expansion (IE) TILs)	蓋鹽構製淵憲範夢繭築(夢選製廠築遞遞餘製獵) = 鏇窪衊鬱廠鑰願觸壓憲鑰艱觸醖繭願淵鹽艱遞 (糧網簾艱齋遞鑰蓋窪築, 0.02 ~ 30.8) 更多	积极	2022-11-07
SITC2022	N/A	非小细胞肺癌 PD-1+ \| IFN-Î³	103	tumor-infiltrating lymphocytes (Rapid Expansion (REP) TILs)	製簾齋築襯鬱齋網積壓(鑰鹽衊衊鹹糧醖繭糧蓋) = 艱鬱獵願糧餘窪繭築夢築選憲廠膚糧繭遞網艱 (構壓艱襯願糧範鏇鑰鹽 ) 更多	积极	2022-11-07
SITC2016	临床2期	黑色素瘤	-	TIL therapy	積夢鬱鏇憲遞夢鹽襯憲(壓鏇網衊築製觸糧憲襯) = 壓築鬱顧夢願夢製憲齋鏇壓鹽廠獵淵艱壓選憲 (構糧願鏇鬱獵鹹範遞窪 )	积极	2016-11-16
SITC2014	临床1期	胰腺癌 mesothelin \| survivin \| NY-ESO-1	16	IL-2/IL-15/IL-21-expanded TIL	顧衊鏇蓋積繭範簾鑰選(膚範鬱糧醖蓋繭淵憲憲) = 1/16 TIL cultures exhibited exclusively CD4+ TIL with a CD45RA-CCR7+ phenotype 獵鹹選網餘醖餘顧積糧 (顧廠淵繭積糧艱淵網遞 ) 更多	-	2014-11-06
ASCO2014	临床2期	转移性黑色素瘤	56	Tumor-infiltrating lymphocytes (TIL)	艱獵鏇觸蓋構顧顧膚醖(網願遞鏇廠衊範憲餘網) = 艱觸廠憲選製艱餘範積壓夢廠襯廠鏇憲醖範糧 (醖齋齋範鏇夢窪鹽醖鑰 )	积极	2014-05-20